Development of Noninvasive, Controlled Release Therapeutics for Glaucoma

January 9, 2013 -
11:45am to 1:00pm

Morgan V. Fedorchak, PhD
Postdoctoral Fellow
S.R. Little LaboratoriesMorgan V. Fedorchak
Departments of Ophthalmology and Chemical Engineering
University of Pittsburgh and the Louis J. Fox Center for Vision Restoration

Dr. Morgan Fedorchak is a Research Assistant Professor and a Post-doctoral Fellow at University of Pittsburgh. Prior to this she was a Graduate Student Researcher at Medical Devices Laboratory and an Animal Technician at McGowan Institute for Regenerative Medicine.

She received her PhD in 2011 from the University of Pittsburgh in the Department of Chemical Engineering and Ophthalmology. Her focus was in the development and pre-clinical testing of controlled-release formulations of ocular therapeutics.

Presentation abstract

One of the main risk factors in glaucoma is an unsafe increase in intraocular pressure (IOP). IOP reduction in patients with glaucoma is typically accomplished through the administration of medicated eye drops several times daily, the difficult and frequent nature of which contributes to patient compliance rates estimated to be as low as 50%. Newer drug delivery methods for glaucoma aimed at improving patient compliance require clinician administration of invasive injections or implants. The purpose of this work is to develop and test controlled release formulations that provide one month or more of therapeutic levels of glaucoma medication in a noninvasive, patient-administered system. We hypothesize that this type of novel treatment method will address the issues of both compliance and poor bioavailability inherent to traditional eye drop medication while avoiding the need for clinician involvement or more invasive techniques.


Location and Address

Eye and Ear Boardroom, 5th floor, Eye and Ear Institute